STOCK TITAN

60 Degrees Pharmaceuticals (SXTP) S-3 Filings

SXTP NASDAQ

Here are the S-3 shelf registrations from 60 Degrees Pharmaceuticals, Inc. (SXTP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow SXTP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SXTP filings page.

Rhea-AI Summary

60 Degrees Pharmaceuticals, Inc. is registering up to 1,769,593 shares of common stock for resale by existing selling stockholders. These include outstanding shares and shares issuable from pre-funded warrants, Series A and B common warrants, and placement agent warrants issued in a July 30, 2026 private placement. The company is not selling any shares and will receive no proceeds from stockholder resales, only any cash paid upon warrant exercise.

The company is a specialty pharmaceutical business focused on infectious diseases, led by its FDA-approved malaria prophylaxis Arakoda (tafenoquine). It is pursuing additional indications such as babesiosis, chronic babesiosis, and veterinary babesiosis through multiple clinical trials, while also advancing early programs in viral diseases via Celgosivir and Australian Chestnut Extract. Prior financing has included at-the-market offerings and a 1:4 reverse stock split that restored compliance with Nasdaq listing rules.